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ABSTRACT
Background and aims Coeliac disease (CD) is triggered
by an abnormal reaction to gluten. Peptides resulting
from partially digested gluten of wheat, barley or rye
cause inflammation of the small intestinal mucosa.
Previous contradictory studies suggest that oats may
trigger the abnormal immunological response in patients
with CD. Monoclonal antibodies (moAbs) against the
main immunotoxic 33-mer peptide (A1 and G12) react
strongly against wheat, barley and rye but have less
reactivity against oats. The stated aim of this study is to
test whether this observed reactivity could be related to
the potential toxicity of oats for patients with CD.
Methods In the present study, different oat varieties,
controlled for their purity and by their distinct protein
pattern, were used to examine differences in moAb G12
recognition by ELISA and western blot. Immunogenicity of
oat varieties was determined by 33-mer concentration,
T cell proliferation and interferon g production.
Results Three groups of oat cultivars reacting differently
against moAb G12 could be distinguished: a group with
considerable affinity, a group showing slight reactivity
and a third with no detectable reactivity. The
immunogenicity of the three types of oats as well as that
of a positive and negative control was determined with
isolated peripheral blood mononuclear T cells from
patients with CD by measurement of cell proliferation
and interferon g release. A direct correlation of the
reactivity with G12 and the immunogenicity of the
different prolamins was observed.
Conclusions The results showed that the reactivity of
the moAb G12 is proportional to the potential
immunotoxicity of the cereal cultivar. These differences
may explain the different clinical responses observed in
patients suffering from CD and open up a means to
identify immunologically safe oat cultivars, which could
be used to enrich a gluten-free diet.
INTRODUCTION
Coeliac disease (CD) is deﬁned as an alteration of
the mucosa of the proximal small intestine, asso-
ciated with a permanent intolerance to gluten.
Currently, the only effective treatment is a strict
gluten-free diet (GFD).1 The main immunogenic
peptides of gluten belong to a family of closely
related proline- and glutamine-rich proteins called
prolamins. CD is triggered by peptides resulting
from the fragmentation of prolamins, which are
not digested by human proteases.
The identiﬁcation of a 17 amino acid peptide
corresponding to the partially deamidated peptide of
A-gliadin amino acids 57e73 and of the 33-mer
peptide of a-gliadin residues 57e89 contributed to
the demonstration that the highly antigenic gluten
epitopes are located in the proline-rich regions of
gliadin.2e5 The 33-mer immunogenic peptide in
other prolamins such as hordein and secalin has been
demonstrated.6 This oligopeptide is usually themost
Significance of this study
What is already known about this subject?
< The safety of oats in a gluten-free diet (GFD) has
been a topic of debate for several years. At the
nutritional level, oats are an important source of
proteins, fat, vitamins, minerals, and fibres, and
could therefore be beneficial for people with
coeliac disease (CD). In addition, the palatability
of oats and their wide availability could also
contribute to the acceptability of a diet without
wheat, barley and rye.
< The difference in type of oats used, the purity
and study design have not allowed a clear
answer as to whether oats are safe or not for all
patients with CD. Current beliefs are that pure
oats are safe for most people with CD, and
contamination with other cereal sources is the
main problem facing people with CD.
What are the new findings?
< In this study we show, using a new antibody
raised against the toxic fragment, that oat
immunogenicity for patients with CD varies
according to the cultivars. We could distinguish
three groups of oat cultivars reacting differently
against the antibody: a group with considerable
affinity, a group showing slight reactivity and
another with no detectable reactivity.
< The potentially immunotoxicity of the three
types of oats was determined by T cell
proliferation and interferon g release. We have
proved that the reactivity of this antibody with
cereal storage proteins of different varieties of
oats was correlated with the immunotoxicity of
the dietary grains.
< This gives a rational explanation for why only
some oats trigger an immunological response.
< Additional table are published
online only. To view these files
please visit the journal online
(http://gut.bmj.com).
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bioactive gluten peptide recognised by gluten-speciﬁc Tcell lines
from HLA-DQ2+ CD donors; however, it is not the only gluten
peptide sequence which is harmful for patients with CD and,
furthermore, patients with CDmay react against glutenins found
in these cereals.4 Attempts to demonstrate 33-mer peptides in oats
have not been successful yet, although some patients with CD
have HLA-DQ2-reactivemucosal Tcells that recognise peptides in
oats which may cause mucosal inﬂammation.7
The presence of oats in a GFD is still a subject of debate. Oats
differ from other cereals in their prolamin content. The
percentage of proline and glutamine (amino acids abundant in
toxic regions) in avenin is lower than in other toxic cereals. Some
clinical researchers state that patients with CD tolerate oats
without signs of intestinal inﬂammation.8e10 Several countries
permit the use of oats in ‘gluten-free’ productsdfor example,
Gluten Free Oats. According to the Codex Standard for food
for special dietary use for persons intolerant to gluten, CODEX
STAN118-1979 (revised 2008, http://www.codexalimentarius.
net/web/more_info.jsp?id_sta¼291), oats can be tolerated by
most but not all people who are intolerant to gluten. Therefore,
whether or not oats that are not contaminated with wheat, rye
or barley in foods covered by this standard can be allowed may
be determined at the national level. Moreover, according to the
Commission Regulation (EC) No 41/2009 (http://eur-lex.
europa.eu/LexUriServ/LexUriServ.do?uri¼OJ:L:2009:016:0003:0
005:EN:PDF) concerning the composition and labelling of
foodstuffs suitable for people intolerant to gluten, a major
concern is the contamination of oats with wheat, rye or barley
that can occur during grain harvesting, transport, storage and
processing. Therefore, the risk of gluten contamination in
products containing oats should be taken into consideration
with regrad to labelling of those products. Some cross-reactivity
with gliadin-speciﬁc antibody has been attributed to wheat
contamination in oat-based food.10
In contrast, other studies conﬁrmed the toxicity of oats in
certain types of patients with CD. Arentz-Hansen et al7
described the intestinal deterioration suffered by some patients
with CD following the consumption of oats while on a GFD.
Avenin can trigger an immunological response in these patients
similar to the response produced by the gluten of wheat, rye or
barley. The monitoring of 19 adult patients with CD who
consumed 50 g/day of oats over 12 weeks showed that one of
the subjects was sensitive to oats.11 Therefore, it is critical to
clarify either qualitatively or quantitatively the potential
immunotoxicity of oats to patients with CD.7 10
In a previous work, we obtained two monoclonal antibodies
(moAbs) G12 and A1 against the 33-mer.12 Our results suggested
that the reactivity of these moAbs was correlated with the
potential immunotoxicity of the dietary grains from which the
proteins were extracted.6 13 These antibodies are able to recog-
nise with great sensitivity peptides (besides the 33-mer peptide)
immunotoxic for patients with CD. The sensitivity and epitope
preferences of these antibodies were found to be useful for
detecting gluten-relevant peptides to infer the potencial toxicity
of food for patients with CD.
The moAb G12 showed cross-reactivity that served to detect
a certain amount of oat avenins, although with lower sensitivity
than hordein, gliadin and secalin.12 The oat controversy appeared
to be a unique case to explore that issue, because cases of inter-
mediated immunotoxicity could be expected and correlation of
potential toxicity and analytical signals could be assessed.
With this background, the aim of the present study was to
determine whether the most sensitive antibody for 33-mer, G12,
could be used to identify varieties of oats that are potentially
toxic for patients with CD by establishing a possible correlation
between the reactivity of the different varieties and the capacity
to activate coeliac T cells from patients with CD.12
We have shown that the reactivity of moAb G12 with cereal
storage proteins of different varieties of oats was correlated with
the immunotoxicity of the dietary grains from which the
proteins were extracted. We showed that the intensity of
the signal obtained with this antibody was proportional to the
responses in terms of cell proliferation and interferon g (IFN-g)
release. Our results suggested that the speciﬁc moAb G12 is
a reliable tool for detecting oat varieties potentially safe for
patients with CD, permitting the enrichment of a GFD.
MATERIALS AND METHODS
Plant materials
Oats (Avena sativa L.) from different cultivars, accessions
OM719, OE717, OL715, OA729, OH727, OC723, OF720,
OR721 and OP722, were obtained from Spanish and Australian
commercial sources. Rice (J. Sendra variety, Spain) and wheat
(Triticum durum, Don Pedro variety, Spain) were used as a nega-
tive and positive control, respectively.
Preparation of prolamin solutions
Oat and rice ﬂours were prepared by grinding the kernels of the
oat varieties and rice, and extracted as described in Cornell
et al.14 Gliadin (Sigma, St Louis, Missouri, USA) was prepared in
60% (v/v) ethanol.
33-mer peptide and antigliadin 33-mer moAb
The 33-mer peptide, the G12 moAb and its derived horseradish
peroxidase (HRP)-conjugated moAb (G12eHRP) were supplied
by Biomedal (Sevilla, Spain).
DNA extractions and PCR amplification
Extraction of DNA was performed using a modiﬁed cetyl-
trimethylammonium bromide (CTAB) method. DNA concen-
trations were determined by UV absorption. The purity of the
DNA solution was assessed by the 260/280 nm absorption ratio.
Oligonucleotides used in this work were provided by Biomedal
and are listed in Supplementary table S1. PCR (Biotools B&M
Significance of this study
How might it impact on clinical practice in the foreseeable
future?
< The incorporation of some varieties of oats in food products
not only may improve the nutritional quality but may provide
a treatment for various illnesses and would be welcomed by
patients with CD. Our work may explain the apparently
contradictory previous studies relating to the safety of oats for
patients with CD. Our study provides new insights about the
oat dilemma in CD and suggests practical methods to select
tolerable varieties of oats for patients with CD.
< Our results suggested that the specific antibody is a reliable
tool for detecting varieties of oats potentially safe for patients
with CD, permitting the enrichment of a GFD. This work should
also be taken into consideration in food safety regulations, in
particular labelling of gluten-free products that may contain
oats. The design of clinical research about oat effect on
patients with CD should consider this study to remark the
importance of the oat source.
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Labs, Madrid, Spain) was performed following the manufac-
turer ’s protocol.
Competitive ELISA
We used R5 ELISA according to the supplier ’s instructions
RIDASCREEN kit (Gliadin competitive R-Biopharm AG,
Darmstadt, Germany). MoAb G12 competitive ELISA was
carried out according to Morón et al.12
Protein analysis by sodium dodecyl sulfateepolyacylamide gel
electrophoresis (SDSePAGE) and western blotting
SDSePAGE and immunoblotting were performed under standard
conditions. SDSePAGE was prepared with 12.5% acrylamide.
Proteins in the gel were stained with silver staining or transferred
to a polyvinylidene ﬂuoride (PVDF) membrane. The PVDF
membranes were incubated with G12. After washing, antimouse
immunoglobulin G (IgG) phosphatase antibody (Sigma) was
added.
Matrix-assisted laser desorption/ionisation time-of-flight mass
spectrometry (MALDI-TOF MS) analysis
The MALDI-TOF MS analysis was performed as described by
Hernando et al.15 Identiﬁcation of avenin by MALDI-TOF MS
showed characteristic protonated mass patterns.
Pepticetrypsicechymotrypsin digestion
The alcohol-soluble protein fraction was extracted from whole
ﬂour and subjected to peptic, trypsic and chymotrypsin
sequential digestion according to Ehren et al.13
Transglutaminase deamidation
The avenin peptides of the different oat varieties as well as the
gliadin and oryzein control were treated with guinea pig liver
tissue transglutaminase (tTG) (Sigma) in the presence of 2 mM
CaCl2, at 378C for 4 h.16
Histological and serological analysis of subjects
Ten patients with biopsy-proven active CD were included in this
study and ﬁve healthy patients were considered as the control
group. The diagnosis of CD in the patients was determined by
serological screening tests accompanied by biopsy of the small
intestine according to the criteria of Marsh17 and conﬁrmation
of a clinical response to gluten elimination from the diet.
Subjects were prospectively screened for CD using anti-
endomysial antibodies, antigliadin antibodies, tTG antibodies
and CD-speciﬁc HLA (human leucocyte antigen) typing
(table 1). Venous blood was taken at the time of index biopsy.
The healthy control patients were serologically negative for
antiendomysial, antigliadin and tTG antibodies. The study
was approved by the ethic committee of the ‘Virgen de las
Nieves’ Hospital, Granada (Spain), and informed consent was
obtained.
Peripheral blood mononuclear cells (PBMCs) and cell cultures
PBMCs from patients with active CD on a gluten-containing
diet were isolated from 6 ml of heparinised blood by Histopaque
gradient centrifugation and cultured at a density of 13106 cells/ml
in RPMI-1640 culture medium. After 48 h, PBMCs were
incubated with avenin, gliadin and oryzein peptides (50 mg/ml).
Cell proliferation analysis
T cell proliferation was determined after 48 h of incubation
using the ELISA 5-bromo-2-deoxyuridine cell proliferation test
(Millipore Chemicon, Temecula, California, USA). The stimu-
lation index (SI) value was calculated by dividing the mean
absorbance/10 at 450 nm after stimulation by the mean absor-
bance of T cells exposed to the culture medium alone (negative
control) and divided by 10. The proliferation of PBMCs exposed
to the different fragments of avenins was expressed as the mean
ﬂuorescent intensity 48 h after exposure.
IFN-g production
Supernatants from PBMC culture were collected after 48 h and
stored at 808C for IFN-g determination using a commercial
ELISA kit in accordance with the manufacturer ’s instructions
(Thermo Scientiﬁc, Madrid, Spain). Standards were run on each
plate. The sensitivity of the assay was <2 pg/ml.
Statistical analysis of T cell and IFN-g assays
Each experiment was carried out in duplicate on separate days.
Data are expressed as mean6SD. All statistical analysis was
performed with the STATGRAPHICS program. When the
interaction was signiﬁcant, the differences between groups were
examined by one-factor analysis of variance (ANOVA). A
Bonferroni-corrected Student t test was used to compare the
individual means. A statistical probability of p<0.05 was
considered signiﬁcant.
RESULTS
Determination of the purity of oat samples
In the present study, the purity of the oat samples was carefully
controlled, ﬁrst by a visual examination to isolate individual
grains and avoid the presence of grains from other cereals, and
secondly by PCR18 for the detection of different cereal DNAs
(wheat, rye and barley) in oat samples.
To detect cereal contamination (wheat, rye and barley) in the
different oat varieties, speciﬁc target sequences encoding
Table 1 Clinical data of patients with coeliac disease
Patient Sex
Age
(years)
Atrophy grade
(Marsh criteria) AAEM AATG HLA-DQB1 HLA-DRB1
Coeliac 1 Male 6 III b + 252 0201e0202 3e7
Coeliac 2 Female 3 III a + 20 0201e0202 3e7
Coeliac 3 Male 13 III b e 2 0202e0301 7e11
Coeliac 4 Female 5 III b + 102 0201e0604 3e11
Coeliac 5 Female 9 III b + 139 0201e0202 3e7
Coeliac 6 Female 2 III b + 15 0302e0301 4e4
Coeliac 7 Female 4 III b + 28 0201e0501 1e3
Coeliac 8 Female 7 II + 111 0201e0202 3e7
Coeliac 9 Male 10 III b + 165 0202e0301 7e11
Coeliac 10 Male 5 III b + 118 0201e0202 3e7
AAEM, antiendomysial antibody; AATG, antitransglutaminase antibody, expressed as U/ml; HLA, human leucocyte antigen.
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fragments of gliadin, secalin, hordein and avenin were chosen for
ampliﬁcation. The amplicon length of the different cereals varied
from 104 bp for oats, to 164 bp for barley and 181 bp for wheat
and rye. In these experiments, negative results were obtained
with the PCR speciﬁc for wheat, rye and barley in oat samples;
however, positive results were obtained when the oat- and
18S-speciﬁc primers were used (ﬁgure 1). Wheat ampliﬁcation
showed positive results with the PCR speciﬁc for 18S
and gliadin, and rye DNA was present in lower amounts in
this sample. As shown in ﬁgure 1, the analysis of the DNA
ampliﬁcation products by agarose gel electrophoresis conﬁrmed
that none of the oat samples was contaminated with wheat,
barley, rye or mixtures of these cereals.
Analysis of avenin variability of the oat cultivars by
MALDI-TOF MS and SDSePAGE
We used MALDI-TOF MS to analyse the prolamin fractions in
oats, and to ﬁnd ‘molecular signatures’ to identify and charac-
terise the different oat varieties. The spectra of the avenin
fractions of the different oat varieties obtained by MALDI-TOF
MS and the electrophoretic distribution of the prolamins by
SDSePAGE revealed distinct patterns that could allow their
further identiﬁcation (ﬁgure 2). In both MALDI-TOF MS and
SDSePAGE, the distribution of molecular weights ranged
between 19 and 31 kDa, in agreement with previous work
describing avenins.18 19 The number and relative intensity of the
peaks obtained by MALDI-TOF MS in the nine oat cultivars
were very variable, indicating that oats differ in their avenin
complement. Variability in protein length and distribution was
also evident by SDSePAGE. These results indicate the presence
of different prolamin subunits in the oat varieties, which differ
in both their amino acid composition and length.
Relative affinity of the moAb G12 for different varieties of oats
To determine whether the moAb G12 had distinct reactivity to
the different oat varieties, the afﬁnity of the moAb G12 was
determined by competitive ELISA. The oat varieties tested
showed different afﬁnities for the moAb G12 (ﬁgure 3A).
Therefore, three groups of oat varieties could be clearly distin-
guished depending on their recognition by the moAb G12:
a group with high afﬁnity towards the antibody (OM719,
OA729 and OE717), a group with intermediate recognition
Figure 1 Evaluation of the presence of amplifiable DNA in oat varieties,
wheat and rice by PCR. An ethidium bromide-stained agarose gel with oat,
barley, rye and wheat PCR amplification products of two representative
oat samples and other cereals (wheat and rice). MW, DNA molecular
weight marker. Positive controls: DNA of these cereals amplified with 18S
primers. The corresponding primers used were: (a) 18S; (b) u-avenin;
(c) u-hordein; (d) u-secalin; and (e) u-gliadin. A representative example
from the two biological replicates performed is shown.
Figure 2 Comparison of avenin fractions extracted from the oat varieties studied. Avenin spectra were determined by matrix-assisted laser
desorption/ionization time-of-flight mass spectrometry of the nine oat varieties. Analysis of proteins extracted from the oat varieties by sodium dodecyl
sulfateepolyacrylamide gel electrophoreis (SDSePAGE). MW, protein molecular weight marker.
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(OH727, OL715 and OC723) and another group comprising oats
that were not recognised by moAb G12 (OF720, OR721 and
OP722). The alternative anti-33mer moAb A1 also provided
equivalent results (data not shown).
In order to quantify the afﬁnity of the oat varieties for the
moAb G12, the IC50 and the CR were determined for each
variety (ﬁgure 3B). The IC50 is deﬁned as the concentration that
produces a reduction of 50% in the peak signal in the ELISA. The
CR was determined as (IC50 of the oat variety that presents the
greatest afﬁnity for the antibody/IC50 of each variety assayed)3
100. Varieties OE717 and OA729 showed a CR of w60% and
75%, respectively, with respect to the most sensitive variety
(OM719). Varieties OH727, OL715 and OC723, with a CR of 25,
24 and 12%, respectively, were recognised by the moAb G12, but
with a lower sensitivity. The avenins of OF720, OR721 and
OP722 were not recognised by the moAb G12, as was the case
for the negative control (rice).
In order to conﬁrm the ELISA results with another immu-
nological technique and to identify the protein pattern with
cross-reactivity to the anti-33-mer antibody, immunoblotting
electrophoresis analyses were performed. The results (ﬁgure 3C)
showed that the moAb G12 had afﬁnity for the varieties
OM719, OA729, OE717, OH727, OL715 and OC723. However,
the antibody did not react with the varieties OF720, OP722 and
OR721. The variability in reactivity demonstrated by western
blot thus correlated with the previously presented ELISA results.
These results suggested the presence of different prolamin
subunits in the oat varieties, differing in both their amino acid
composition and length.
Another antibody speciﬁc for the sequence QQPFP (R5) was
used to analyse the different oat varieties. The results obtained
with R5 demonstrate that this antibody, like G12, was able to
detect the same six oat varieties as the anti-33-mer antibodies. In
the varieties OM719, OA729, OE717 and OH727 the values for
the peptide QQPFP ranged between 25 180 and 97 860 mg of
peptide per gram of cereal, which according to the instructions of
the supplier (Gliadin competitive R-Biopharm AG, Darmstadt,
Germany) would correspond to values >100 ppm of gliadin. The
varieties OL715 and OC723 were also recognised by the R5
antibody, although with lower sensitivity than the aforemen-
tioned varieties. In contrast, the varieties OF720, OR721 and
OP722 presented levels of gliadin below 5 ppm. Therefore, the
results obtained with R5 were similar to those reported in this
work with the anti-33-mer antibodies. In order to avoid false
positives, the purity of the samples was monitored molecularly.
Earlier works stated that the reactivity of R5 against certain
foods prepared with oats is due to cross-contamination with
wheat, barley or rye, rather than a direct recognition of epitopes
of this antibody in the oat prolamins.18 However, the results
obtained in this work clearly demonstrated that R5 was able to
recognise, although with differing afﬁnity, different oat varieties
of veriﬁed purity.
Figure 3 Relative affinity of the monoclonal antibody (moAb) G12 for
different oat varieties and gliadin. (A) Competitive ELISA using the anti-
33-mer horseradish peroxidase-conjugated G12 to determine the relative
affinity of this antibody for the different varieties of oat. Three assays
were performed, with three replicates of each. (B) IC50 and CR of the
different oat varieties. N.A., not applicable. (C) Western blot analysis of
toxic fractions from different oat prolamins. Membranes were stained
with the moAb G12. The colour code for labelling the varieties is the
same as that used in A and B. MW, protein molecular weight marker.
Figure 4 Detection of the concentration of the 33-mer peptide in
different oat varieties. The concentration of 33-mer was determined by
competitive ELISA using the monoclonal antibody (moAb) G12
conjugated to horseradish peroxidase. Different independent dilutions
were tested for each oat variety, each with three repetitions. The
percentage of 33-mer of the variety assayed with respect to that of the
most reactive variety (OM719). *The concentration of the 33-mer was
lower than the limit of quantification of the competitive ELISA for the
detection of 33-mer (5.4 ng/ml). N.A., not applicable.
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Determining the concentration of immunoreactive peptides
in oats
To evaluate the relative amount of immunotoxic epitopes
present in the prolamins of different oat varieties, one variety
was chosen from each of the three groups previously identiﬁed
for their afﬁnity towards the moAb G12. Thus, OM719 repre-
sented the group with greatest afﬁnity towards the moAb G12,
OH727 those of intermediate reactivity and OF720 those not
recognised by this antibody. The presence of immunoreactive
peptides was determined by the moAb G12 competitive ELISA,
using the 33-mer peptide as the standard curve. The presence of
33-mer and close analogues in the most reactive oat variety,
OM719, was of the order of 1340 ng/mg of avenin (ﬁgure 4). In
OH727, the levels of 33-mer were some fourfold lower than
in OM719. However, in the case of OF720, the concentration
of 33-mer was reduced >1300-fold with respect to OM719,
reaching levels undetectable by this method. This result was
consistent with earlier results obtained using IC50 and CR, and
by western blot. At the same time, these results indicated the
enormous difference between some varieties regarding the pres-
ence of sequences that are immunoreactive for patients with CD.
Correlation between moAb G12 reactivity and immunogenicity
of different oat varieties
To determine whether the variations in the reactivity of the anti-
33-mer G12 in the different oat varieties were correlated with
the greater or lesser immunogenicity of the cereal, we directly
challenged the cereal extracts with relevant cells obtained from
patients with CD. The clinical and immunological characteristics
of patients with CD are presented in table 1.
Immunogenicity was determined by T cell proliferation and
IFN-g production. Three cultivars of oats were selected; one
variety was chosen from each previously identiﬁed group
(OM719, OH727 and OF720). We tested whether there was
a correlation between their potential immunotoxicity for
patients with CD and their reactivity with the moAb G12.
The avenin of the oat varieties, gliadin and oryzein were
subjected to peptic, trypsic and chymotrypsin sequential
digestion and treated with tTG.
Cell proliferation and IFN-g release in the culture medium
were measured as indexes of lymphocyte activation. We found
a signiﬁcant increase in the T cell proliferation in cultures
incubated with OM719 and gliadin (SI¼1.360.7 and 1.860.9,
respectively), and also with OH727 (SI¼1.0260.5). These results
clearly showed that gliadin and OM719 displayed the
highest activity, being the most potentially immunogenic
(ﬁgure 5). The incubation with OF720 increased cell prolifera-
tion (SI¼0.6560.4) similar to incubation with oryzein
(SI¼0.6260.3). We included the values presented in healthy
patients (control) as reference values to compare the effect of
peptides in patients with CD under the same conditions of cell
culture.
Release of IFN-g in the culture medium after the exposure of
coeliac peripheral T lymphocytes to deamidated avenin peptides
was assessed (ﬁgure 6). According to this assay, gliadin and
prolamins from OM719 were very immunogenic, with the
highest values of IFN-g release (9.460.76 and 7.960.57 pg/ml,
respectively), whereas the exposure to OH727 induced a lower
mean value of IFN-g (4.860.95 pg/ml). Finally, OF720 and
oryzein were the least immunogenic (3.461.09 and 2.360.89 pg/
ml, respectively).
DISCUSSION
In this work, we have shown that there is a wide range of
reactivity of different oat cultivars to the anti-33-mer G12.12
Furthermore, the reactivity of isolated coeliac T cells to three
different oat varieties ranging from none to maximal moAb G12
recognition showed a direct correlation of the T cell reactivity
and moAb G12 reactivity. Traditionally, treatment with a GFD
has excluded wheat, barley, rye and also oats.20 However, there
is still some debate about the safety of oats.10 The safety of oats
in individuals with CD has been widely investigated.10 Several in
Figure 5 Proliferative responses of T
cells to deamidated peptides of
prolamin from three different oat
varieties. Peripheral blood mononuclear
cells were stimulated by tissue
transglutaminase-treated prolamin
digest for 48 h. Gliadin and oryzein were
used as the positive and negative
control, respectively. The experiments
were performed in duplicate and the
mean stimulation index (SI) 6SD is
shown. The SI values of T cells exposed
to prolamin digests were statistically significant with respect to (A) the control (healthy patients) and (B) oryzein. *p<0.05; **p<0.005.
Figure 6 Interferon g (IFN-g)
production by T cells with prolamin
digests from three different oat
varieties. T lymphocytes were
stimulated with digested prolamins after
treatment with tissue transglutaminase.
IFN-g production was evaluated by
ELISA after 48 h of incubation. The
results are shown as the means of
duplicate wells and expressed as pg/ml.
Gliadin and oryzein were used as the
positive and negative control, respectively.
Significant with respect to (A) healthy controls and (B) oryzein. *p<0.05; **p<0.005.
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vivo and in vitro studies indicated that the majority of patients
with CD could tolerate moderate amounts of pure oats.8 10 21 In
contrast, other authors showed clear evidence suggesting that
avenins have the ability to induce the activation of mucosal T
cells, causing gut inﬂammation and villous atrophy.7 11 22 23
These results suggested that intolerance to oats exists in some
patients with CD.7
Comparison of the different studies are complicated by the
different study designs, the different conditions used in the
testing, the number of subjects included in each study and
the reporting of the purity control of the oat material used in the
clinical trials. Another relevant factor in different designs is the
absence of information on the oat variety used. Silano et al24
investigated the immunogenic effect of avenins from four oat
cultivars using peripheral lymphocytes from patients with CD.
The results obtained in this work show that there are in fact
differences in immunogenicity in the oat varieties studied. In
contrast to those authors, we found that some varieties were not
reactive against the T cells of patients with CD.
In our work, ﬁrst we have examined whether the low but
signiﬁcant reactivity of the moAb G12 to oats was due to any
potential cross-contamination, as suggested elsewhere, by PCR
analysis, and secondly, we have studied the importance of the
cultivar in moAb G12 recognition.18 For this study, the purity of
the oat samples was carefully controlled and shown to be free
from contamination by other cereals that was reported as an
intermittent problem that could potentially skew trial results.
Three oats groups could be distinguished based on their
recognition by moAb G12: a group with considerable afﬁnity
towards the antibody, a group with moderateelow recognition
and another group that was not recognised at all by the anti-
body. We conﬁrmed these results by MALDI-TOF, SDSePAGE
and western blot by showing that the number, relative intensity
of the peaks and protein proﬁle obtained for the nine oat varieties
differ from one another.
A direct correlation of the reactivity with moAb G12 and the
immunogenicity of the different prolamins was observed by in
vitro studies. In fact, prolamin peptides from OM719, and to
a lesser degree OH727, could be potentially immunotoxic,
whereas those from OF720 proved to be non-active in triggering
both T cell proliferation and IFN-g release. These results could
also explain previous contradictory results described elsewhere
relating to the potential oat toxicity for patients with CD.
Future experiments based on the method described by Anderson
et al2 and Tye-Din et al4 will be carried out. The next logical set
of experiments would involve an acute 3 day oat challenge of
patients on a GFD, with blood sampling at 6 days.
It is worth mentioning that gliadin was at least 40- to 400-
fold more reactive to moAb G12 than any of the reactive tested
avenins. Catassi et al25 demonstrated that the ingestion of
contaminated gluten should be kept lower than 50 mg/day in
the treatment of CD. Based on the reactivity of the G12 anti-
body against the different oat varieties and gliadin and on the
results published by Catassi et al,25 the tolerance to the most
toxic oats might be in the range of 2e20 g/day. Based on
previous literature it appears that the amount of pure oats
considered within the range of safe limits is a minimum of 20 g/
day.10 Therefore, the limits for potential immunotoxicity
inferred from moAb G12 oat reactivity were of the same order of
magnitude as clinical assays with no consideration of the
intrinsic potential of the oat cultivar. Furthermore, the oat
varieties identiﬁed as non-immunogenic in T cell assays and by
moAb G12 could be proposed for their use as well-tolerated
cereals recommended for a GFD.
The interest in oats for human consumption has increased in
recent years because of the widely recognised nutritional and
health beneﬁts of this cereal.10 The incorporation of some oat
varieties in food products may not only improve the nutritional
quality but could act also a treatment for various illnesses.
By dissecting the reactivity of moAb G12 to different oat
cultivars and its correlation in biological assays with T cells, we
have shown that there is a wide range of variation of potential
immunotoxicity of oat cultivars. We also demonstrated that
there is no strict correlation between total gluten amount and
potential immunotoxicity due to the fact that some 33-mer
analogue epitopes may be much less immunogenic and require
higher doses to provoke an equivalent toxic effect. Our obser-
vations suggest that moAb G12-based immunotechniques
appear to be a pragmatic method to evaluate potential immu-
notoxicity. Our approach offers a new tool to conduct proper
clinical trials in order to conﬁrm the in vitro results.
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